AGE-RELATED MACULAR DEGENERATION (AMD)

This study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots (geographic atrophy) in people with dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the drug or a sham inj…

This study tests a small telescope implant (SING IMT) for people with advanced age-related macular degeneration (AMD) who have severe central vision loss in both eyes. Participants must be 55 or older, have had cataract surgery at least 6 months prior, and have stable vision. The…

This study tests whether taking an oral medication (dimethyl fumarate) for 12 months can slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 90 participants aged 55–85 with geographic atrophy will receive the d…

This study tests two experimental drugs, pozelimab and cemdisiran, alone or together, to see if they can slow the growth of blind spots (geographic atrophy) in people with advanced dry age-related macular degeneration. About 975 adults with moderate vision loss will receive injec…

This study tests whether using an AI tool (VeriSee) to screen for diabetic retinopathy and age-related macular degeneration in regular doctor visits can catch these eye diseases earlier than standard exams. About 4,300 adults with diabetes or aged 50+ will be randomly assigned to…

This study tests whether a 6-month online spin cycling program can improve vision and daily function in veterans aged 65-89 with intermediate age-related macular degeneration (AMD). Participants will exercise together from home while researchers measure changes in contrast sensit…

This study aims to find protein markers in blood and eye fluids that are linked to three major eye diseases: age-related macular degeneration, diabetic retinopathy, and retinal detachment. Researchers will collect samples from about 260 participants during routine care. The goal …

This study looks at new ways to measure how well the eye adapts to darkness in people with early age-related macular degeneration (AMD) and in healthy volunteers. The goal is to find reliable tests that can be used in future treatment trials. Researchers will track changes over t…

This study watches how the eyes of 50 people with wet age-related macular degeneration respond to a higher dose (8mg) of the drug Eylea during the first two months. Researchers use eye scans to measure fluid changes and vision improvements. The goal is to understand early treatme…